Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
Not yet recruiting
Jazz Pharmaceuticals
Phase 2
2024-06-01
This phase II trial tests how well defibrotide works in preventing transplant-associated
thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing
tandem transplants (hematopoietic stem cell transplant [HSCT]). TMA is a potential
life-threatening complication of stem cell transplant. TMA is a possible side effect of the
chemotherapy (conditioning regimen) patients receive to help treat high-risk neuroblastoma,
because these medicines can sometimes damage the blood vessel walls in the body. This damage
leads to formation of tiny blood clots in organs, especially the kidney. This then causes
organ damage and leads to problems with how they function. This study may help researchers
learn how defibrotide may help prevent TMA before it starts, or help treat it once it starts
among patients with high-risk neuroblastoma undergoing tandem transplants.
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
Not yet recruiting
University of California, San Francisco
Phase 2
2024-06-01
This phase II trial tests how well defibrotide works in preventing transplant-associated
thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing
tandem transplants (hematopoietic stem cell transplant [HSCT]). TMA is a potential
life-threatening complication of stem cell transplant. TMA is a possible side effect of the
chemotherapy (conditioning regimen) patients receive to help treat high-risk neuroblastoma,
because these medicines can sometimes damage the blood vessel walls in the body. This damage
leads to formation of tiny blood clots in organs, especially the kidney. This then causes
organ damage and leads to problems with how they function. This study may help researchers
learn how defibrotide may help prevent TMA before it starts, or help treat it once it starts
among patients with high-risk neuroblastoma undergoing tandem transplants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
